<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00649883</url>
  </required_header>
  <id_info>
    <org_study_id>V70P6</org_study_id>
    <nct_id>NCT00649883</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to &lt;60 Months</brief_title>
  <official_title>A Phase II, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Investigational Vaccine and Active Influenza Vaccine in Healthy Children Aged 6 to &lt;60 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This a multicenter phase II trial will evaluate safety and immunogenicity of two 0.25 mL or
      0.5 mL doses of investigational influenza vaccine and active control influenza vaccine in
      healthy children aged 6 to &lt;60 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of one and two doses of investigational vaccines or active control influenza vaccine in unprimed healthy children aged 6 months to &lt;36 months.</measure>
    <time_frame>211 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immunogenicity of two doses of investigational influenza vaccine or active control influenza vaccines, as measured by HI assay in children aged 36 to &lt;60 months.</measure>
    <time_frame>211 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Trivalent Inactivated vaccines Novartis</intervention_name>
    <description>Children 6 to &lt;36 months of age will receive two 0.25 mL doses, and children 36 to &lt;60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Trivalent Inactivated vaccines</intervention_name>
    <description>Children 6 to &lt;36 months of age will receive two 0.25 mL doses, and children 36 to &lt;60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children of 6 to &lt;60 months of age, whose parents/legal guardians have given written
             informed consent prior to study entry.

          -  In good health as determined by: medical history, physical examination, clinical
             judgment of the investigator.

          -  Able to comply with all study procedure

        Exclusion Criteria:

          -  Any serious disease, such as: cancer,autoimmune disease (including rheumatoid
             arthritis), diabetes mellitus, chronic pulmonary disease, acute or progressive hepatic
             and renal disease, acute or progressive neurological or neuromuscular disease;

          -  History of any anaphylaxis or serious reaction following administration of vaccine, or
             hypersensitivity to eggs, egg protein, chicken feathers, influenza viral protein, or
             any other vaccine component, chemically related substance, or component of the
             potential packaging materials;

          -  Known or suspected impairment/alteration of immune function, including:
             immunosuppressive therapy, cancer chemotherapy, receipt of immunostimulants within 60
             days prior to Visit 1, receipt of parenteral immunoglobulin known HIV infection or
             HIV-related disease;

          -  Bleeding diathesis;

          -  Surgery planned during the study period;

          -  Receipt of another investigational agent within 90 days

          -  Laboratory-confirmed influenza disease within 6 months prior to Visit 1;

          -  Ever received two doses of an influenza vaccine before the study

          -  Receipt of an influenza vaccine within 6 months prior to Visit 1;

          -  Experienced a temperature 38.0°C within 3 days prior to Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centro Clínico La Quinta</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínicas Dr. Rafael Montiel</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Carlos Fernando Grazioso Aragón</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Pediátrica Guatemalteca</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Infectologia y rehabilitacion</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guatemala</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=9005</url>
    <description>Link for study results for V70P6 from Novartis Clinical Trials website</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2008</study_first_submitted>
  <study_first_submitted_qc>March 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>vaccine</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

